YOLFTbeta
Suzhou Novoprotein Scientific Co. Ltd. A

Suzhou Novoprotein Scientific Co. Ltd. A

688137 · SHG · Healthcare / Biotechnology

134.67CNY-13.31 (-8.99%)

Price History

Full chart

Market Stats

Previous Close147.98
Open142.00
Day Range134.00 – 144.38
52-Week Range33.20 – 168.03
Volume6.36M
Market Cap11.21B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.19
Dividend Yield0.00%
Beta1.52
50-Day Avg70.91
200-Day Avg49.94

About

Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technology solutions for biopharmaceuticals enterprises. The company offers mRNA vaccine drug raw materials, immunodiagnostic and molecular diagnostic raw materials, gene and cell therapy, molecular research reagents, cytokines, target proteins, cell lines, reference antibody, recombinant antibodies, enzymes and reagents, matrix gel and culture medium, and protein and virus research related products. It offers its products and services in the fields of biopharmaceuticals, mRNA vaccines and drugs, in vitro diagnostics, basic research of life sciences, and other areas. Novoprotein Scientific Inc. was founded in 2009 and is headquartered in Suzhou, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Huaxing Zhu
  • Employees696
  • HeadquartersNo.228, Yunchuang Road, Suzhou, China, 215299, China
  • Websitehttps://www.novoprotein.com.cn

Leadership

  • Dr. Huaxing ZhuFounder, Chairman & GM · b. 1972
  • Mr. Dongye ZhangAccounting Supervisor & CFO · b. 1973
  • Mr. Yingming WangDeputy GM & Director · b. 1975
  • Mr. Yujian ZhaoDeputy GM & Director · b. 1972
  • Mr. Duqiang WangDeputy GM, Secretary & Director · b. 1985

Financials

Income Statement

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue179.84M341.90M264.55M153.19M127.56M146.44M
Growth (%)-+90.11%-22.62%-42.09%-16.73%+14.80%
Cost of Revenue19.32M42.07M36.18M37.27M47.99M48.15M
Gross Profit160.52M299.82M228.37M115.92M79.57M98.29M
Gross Margin89.26%87.69%86.32%75.67%62.38%67.12%
Operating Expense56.70M105.97M115.44M121.81M134.96M164.98M
Operating Income103.82M193.86M112.92M-5.89M-55.40M-66.69M
Operating Margin57.73%56.70%42.68%-3.85%-43.43%-45.54%
EBITDA--130.69M32.36M-19.27M-37.91M
EBITDA Margin--49.40%21.12%-15.10%-25.89%
Net Income83.05M149.01M90.72M12.84M-54.42M-77.78M
Net Income Margin46.18%43.58%34.29%8.38%-42.66%-53.12%
R&D14.97M34.10M41.10M44.79M49.92M64.06M
R&D as % of Total Revenue8.32%9.97%15.54%29.24%39.14%43.75%
Interest Expense1.00M1.80M4.05M3.59M3.59M2.54M
Interest Expense % of Total Revenue0.56%0.53%1.53%2.34%2.81%1.74%

Balance Sheet

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets184.79M513.10M2.33B2.30B2.22B2.15B
Total Liabilities81.69M153.33M133.22M110.43M116.44M116.83M
Total Equity103.10M359.77M2.20B2.19B2.10B2.03B
Cash68.64M189.39M929.92M863.70M647.35M711.10M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-97.56M70.97M3.38M69.16M13.32M-13.36M
Capital Expenditure011.80M69.95M36.77M44.94M44.88M78.89M
Free Cash Flow-85.76M1.02M-33.39M24.22M-31.57M-92.25M
Dividends Paid154.81K1.03M16.29M-35.09M35.09M-
FCF to OCF-87.91%1.43%-988.89%35.02%-237.06%690.38%
Dividend Paid to FCF-1.20%1603.41%-144.87%-111.15%-

Earnings

Report DateOct 28, 2022Dec 31, 2022Apr 26, 2023
EPS Estimate---
EPS Actual0.270.000.16
Surprise---
TimingPre-market-After-hours

Key Statistics & Ratios

Market Cap11.21B
Enterprise Value7.80B
Trailing P/E0.00
Forward P/E0.00
Price / Sales73.37
Price / Book4.30
EPS-1.19
Book Value28.75
Revenue (TTM)152.84M
Gross Profit (TTM)84.79M
EBITDA-72.67M
Profit Margin-54.15%
Operating Margin-66.84%
Return on Equity-4.06%
Return on Assets-2.51%
Shares Outstanding69.92M
Shares Float21.89M
Beta1.52
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20241×
0.50Aug 1, 2024
20231×
0.50Jun 29, 2023